M&A Pharmacies Ltd

	Page
Balance Sheet	1—2
Statement of Changes in Equity	3
Notes to the Financial Statements	4—7

Registered number: 02114634

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	5		4,143		4,846

			4,143		4,846
CURRENT ASSETS
Stocks	6	79,868		79,868
Debtors	7	407,639		538,847
Cash at bank and in hand		50,258		119,218

		537,765		737,933
Creditors: Amounts Falling Due Within One Year	8	(210,268 )		(270,698 )

NET CURRENT ASSETS (LIABILITIES)			327,497		467,235

TOTAL ASSETS LESS CURRENT LIABILITIES			331,640		472,081

NET ASSETS			331,640		472,081

CAPITAL AND RESERVES
Called up share capital	9		200		200
Profit and Loss Account			331,440		471,881

SHAREHOLDERS' FUNDS			331,640		472,081

Page 1

Page 2

M&A Pharmacies Ltd

Balance Sheet (continued)

As At 31 March 2025

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Mohamed Patel

Director

29/12/2025

The notes on pages 4 to 6 form part of these financial statements.

	Share Capital	Profit and Loss Account	Total
	£	£	£
As at 1 April 2023	200	537,858	538,058
Loss for the year and total comprehensive income	-	(49,977 )	(49,977)

Dividends paid	-	(16,000)	(16,000)

As at 31 March 2024 and 1 April 2024	200	471,881	472,081


Loss for the year and total comprehensive income	-	(126,441 )	(126,441)

Dividends paid	-	(14,000)	(14,000)

As at 31 March 2025	200	331,440	331,640

1. General Information

M&A Pharmacies Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 02114634 . The registered office is 1A Lee Brig, Altofts, Wakefield, West Yorkshire, WF6 2JJ.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 10 years.

2.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold	Straight line over fifty years
Leasehold	Straight line over the life of the lease
Motor Vehicles	25% Reducing balance
Fixtures & Fittings	15% Reducing balance

2.5. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

2.6. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

...CONTINUED

Page 4

Page 5

M&A Pharmacies Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2025

2.6. Taxation - continued

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was:

	2025	2024
Office and administration	1	1
Sales, marketing and distribution	18	22

	19	23

4. Intangible Assets

	Goodwill
	£
Cost
As at 1 April 2024	336,505

As at 31 March 2025	336,505

Amortisation
As at 1 April 2024	336,505

As at 31 March 2025	336,505

Net Book Value
As at 31 March 2025	-

As at 1 April 2024	-

5. Tangible Assets

	Land & Property
	Leasehold	Motor Vehicles	Fixtures & Fittings	Total
	£	£	£	£
Cost
As at 1 April 2024	160	15,998	151,225	167,383

As at 31 March 2025	160	15,998	151,225	167,383

Depreciation
As at 1 April 2024	-	15,998	146,539	162,537
Provided during the period	-	-	703	703

As at 31 March 2025	-	15,998	147,242	163,240

Net Book Value
As at 31 March 2025	160	-	3,983	4,143

As at 1 April 2024	160	-	4,686	4,846

Page 5

Page 6

M&A Pharmacies Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2025

6. Stocks

	2025	2024
	£	£
Finished goods	79,868	79,868

7. Debtors

	2025	2024
	£	£
Due within one year
Trade debtors	279	122,097
Prepayments and accrued income	-	11,381
Director 1 Current Account (Debit) - Mr Mohamed Patel	121,393	121,393
Director 2 current account (debit) - Mrs Angela Dean	99,825	99,825
VAT Repayable	45,996	59,997

	267,493	414,693
Due after more than one year
Other debtors	4,424	4,624
M&A and Kajal Investments	17,904	17,904
M&A Rental Properties Ltd	43,444	27,252
Corporation tax recoverable assets	74,374	74,374

	140,146	124,154

	407,639	538,847

8. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	174,032	249,710
Corporation tax	244	244
Other taxes and social security	7,208	8,088
Other creditors	5,000	5,000
Accruals and deferred income	23,784	7,656

	210,268	270,698

Other Creditors represents dividends payable to directors

9. Share Capital

	2025	2024
	£	£
Allotted, Called up and fully paid	200	200

10. Directors Advances, Credits and Guarantees

Included within Debtors are the following loans to directors:

	As at 1 April 2024	Amounts advanced	Amounts repaid	Amounts written off	As at 31 March 2025
	£	£	£	£	£
Mr Mohamed Patel	121,392	-	-	-	-

The above loan is unsecured, interest free and repayable on demand.

Page 6

Page 7

M&A Pharmacies Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2025

Dividends paid to directors

	2025	2024
	£	£
Mr Mohamed Patel	3,500	4,000

Page 7